Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
Conduit Pharmaceuticals (Nasdaq: CDT) has expanded its partnership with Sarborg through an additional license and use agreement to enhance the analysis of its AstraZeneca-acquired assets. The collaboration focuses on applying machine learning algorithms to analyze clinical and safety data for AZD1656, AZD5658, and AZD5904.
Under the six-month non-exclusive, non-transferable license agreement, Sarborg will conduct in-depth analysis of clinical trial data to identify missed insights, drug repurposing opportunities, and data gaps. The partnership aims to evaluate historical trial data and endpoints to identify potential therapeutic benefits in specific patient subgroups, which could optimize future clinical development strategies.
Conduit Pharmaceuticals (Nasdaq: CDT) ha ampliato la sua partnership con Sarborg attraverso un ulteriore accordo di licenza e utilizzo per migliorare l'analisi dei suoi beni acquisiti da AstraZeneca. La collaborazione si concentra sull'applicazione di algoritmi di machine learning per analizzare i dati clinici e di sicurezza per AZD1656, AZD5658 e AZD5904.
In base all'accordo di licenza non esclusiva e non trasferibile della durata di sei mesi, Sarborg condurrà un'analisi approfondita dei dati degli studi clinici per identificare informazioni trascurate, opportunità di riposizionamento dei farmaci e lacune nei dati. L'obiettivo della partnership è valutare i dati storici degli studi e i risultati per identificare potenziali benefici terapeutici in specifici sottogruppi di pazienti, il che potrebbe ottimizzare le strategie di sviluppo clinico future.
Conduit Pharmaceuticals (Nasdaq: CDT) ha ampliado su asociación con Sarborg a través de un acuerdo adicional de licencia y uso para mejorar el análisis de sus activos adquiridos de AstraZeneca. La colaboración se centra en la aplicación de algoritmos de aprendizaje automático para analizar datos clínicos y de seguridad de AZD1656, AZD5658 y AZD5904.
Bajo el acuerdo de licencia no exclusiva y no transferible de seis meses, Sarborg llevará a cabo un análisis exhaustivo de los datos de ensayos clínicos para identificar información perdida, oportunidades de reposicionamiento de fármacos y lagunas en los datos. La asociación tiene como objetivo evaluar los datos históricos de ensayos y los puntos finales para identificar posibles beneficios terapéuticos en subgrupos específicos de pacientes, lo que podría optimizar las estrategias de desarrollo clínico futuras.
콘듀잇 제약 (Nasdaq: CDT)는 아스트라제네카에서 인수한 자산 분석을 강화하기 위해 추가 라이센스 및 사용 계약을 통해 사르보그와의 파트너십을 확장했습니다. 이 협력은 AZD1656, AZD5658 및 AZD5904에 대한 임상 및 안전성 데이터를 분석하기 위해 기계 학습 알고리즘을 적용하는 데 중점을 두고 있습니다.
6개월 비독점적이며 양도 불가능한 라이센스 계약에 따라 사르보그는 임상 시험 데이터에 대한 심층 분석을 수행하여 놓친 통찰력, 약물 재사용 기회 및 데이터 갭을 식별할 것입니다. 이 파트너십의 목표는 과거 시험 데이터와 종료를 평가하여 특정 환자 하위 그룹에서 잠재적인 치료적 이점을 식별하는 것이며, 이는 향후 임상 개발 전략을 최적화할 수 있습니다.
Conduit Pharmaceuticals (Nasdaq: CDT) a élargi son partenariat avec Sarborg par le biais d'un accord de licence et d'utilisation supplémentaire pour améliorer l'analyse de ses actifs acquis auprès d'AstraZeneca. La collaboration se concentre sur l'application de l'algorithme d'apprentissage automatique pour analyser les données cliniques et de sécurité pour AZD1656, AZD5658 et AZD5904.
Dans le cadre de l'accord de licence non exclusif et non transférable de six mois, Sarborg effectuera une analyse approfondie des données des essais cliniques afin d'identifier les informations manquées, les opportunités de repositionnement des médicaments et les lacunes dans les données. L'objectif du partenariat est d'évaluer les données historiques des essais et les résultats afin d'identifier les avantages thérapeutiques potentiels dans des sous-groupes de patients spécifiques, ce qui pourrait optimiser les stratégies de développement clinique futures.
Conduit Pharmaceuticals (Nasdaq: CDT) hat seine Partnerschaft mit Sarborg durch einen zusätzlichen Lizenz- und Nutzungsvertrag erweitert, um die Analyse seiner von AstraZeneca erworbenen Vermögenswerte zu verbessern. Die Zusammenarbeit konzentriert sich auf die Anwendung von Machine-Learning-Algorithmen, um klinische und Sicherheitsdaten für AZD1656, AZD5658 und AZD5904 zu analysieren.
Im Rahmen des sechsmonatigen nicht-exklusiven, nicht übertragbaren Lizenzvertrags wird Sarborg eine eingehende Analyse der Daten klinischer Studien durchführen, um versäumte Erkenntnisse, Möglichkeiten zur Wiederverwendung von Arzneimitteln und Datenlücken zu identifizieren. Ziel der Partnerschaft ist es, historische Studiendaten und Endpunkte zu bewerten, um potenzielle therapeutische Vorteile in bestimmten Patientensubgruppen zu identifizieren, was zukünftige klinische Entwicklungsstrategien optimieren könnte.
- Strategic expansion of data analysis capabilities through machine learning technology
- Potential optimization of drug development pathways through advanced analytics
- Possibility of identifying new therapeutic applications for existing assets
- Short-term agreement duration (6 months) limiting long-term strategic planning
- Non-exclusive license means technology isn't proprietary to Conduit
Insights
Conduit's expanded partnership with Sarborg represents a strategic move to extract additional value from their AstraZeneca-acquired assets through advanced data analytics. The six-month agreement focuses on applying machine learning to re-examine clinical trial data for AZD1656, AZD5658, and AZD5904, potentially uncovering missed insights or patient subgroups that responded positively to treatment.
This approach reflects an increasingly common strategy in the pharmaceutical industry: leveraging computational methods to maximize ROI on existing assets rather than starting development from scratch. The partnership could potentially identify new indications, optimize future trial designs, or reveal valuable patient stratification markers that might have been overlooked in initial analyses.
The non-exclusive, non-transferable license structure suggests a fee-for-service arrangement rather than a deeper strategic alliance. Without disclosed financial terms, it's difficult to assess the monetary commitment, but the short timeframe indicates a focused, exploratory engagement rather than a comprehensive redevelopment effort.
For Conduit, a company with a
- Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with Sarborg Limited (“Sarborg”) to expand the scope of work on Conduit’s acquired AstraZeneca assets, including AZD1656, AZD5658, and AZD5904.
Under the agreement, Sarborg will apply its proprietary machine learning algorithms to conduct an in-depth analysis of Conduit’s clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits, findings that could refine Conduit’s future clinical development strategy.
Sarborg has granted Conduit a non-exclusive, non-transferable license to access its advanced algorithmic platform for the duration of the six-month agreement. The collaboration builds upon the existing Services Agreement between the two parties, which remains in full effect.
“This expanded partnership with Sarborg underscores our commitment to leveraging cutting-edge data science to maximize the potential of our pipeline,” said Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals. “By applying advanced analytics to our clinical datasets, we aim to uncover new opportunities that could enhance the development pathway for our key assets, including AZD1656.”
About Conduit Pharmaceuticals
Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of pharmaceutical executives including Dr. David Tapolczay and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit's future results of operations and financial position, Conduit's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors & Media:
info@conduitpharma.com
FAQ
What assets will Sarborg analyze for Conduit Pharmaceuticals (CDT)?
How long is the new license agreement between Conduit (CDT) and Sarborg?
What is the main purpose of Conduit's (CDT) expanded partnership with Sarborg?
What type of license has Sarborg granted to Conduit (CDT)?
